126 related articles for article (PubMed ID: 31486252)
1. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
3. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
4. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
[TBL] [Abstract][Full Text] [Related]
5. Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity.
Anon B; Largeau B; Girault A; Chantome A; Caulet M; Perray C; Moussata D; Vandier C; Barin-Le Guellec C; Lecomte T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):149-157. PubMed ID: 29774408
[TBL] [Abstract][Full Text] [Related]
6. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
[TBL] [Abstract][Full Text] [Related]
7. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
[TBL] [Abstract][Full Text] [Related]
8. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
9. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.
Argyriou AA; Briani C; Cavaletti G; Bruna J; Alberti P; Velasco R; Lonardi S; Cortinovis D; Cazzaniga M; Campagnolo M; Santos C; Kalofonos HP
Eur J Neurol; 2013 May; 20(5):788-94. PubMed ID: 23252594
[TBL] [Abstract][Full Text] [Related]
10. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
12. Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peripheral neuropathy.
Chen SC; Huang HP; Huang WS; Lin YC; Chu TP; Beaton RD; Jane SW
Eur J Oncol Nurs; 2020 Dec; 49():101834. PubMed ID: 33120223
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
15. SK3 Gene Polymorphism Is Associated with Taxane Neurotoxicity and Cell Calcium Homeostasis.
Rua C; Guéguinou M; Soubai I; Viel E; Potier-Cartereau M; Chantome A; Barbe C; Bougnoux P; Barin-Le Guellec C; Vandier C
Clin Cancer Res; 2018 Nov; 24(21):5313-5320. PubMed ID: 30037821
[No Abstract] [Full Text] [Related]
16. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.
Palugulla S; Devaraju P; Kayal S; Narayan SK; Mathaiyan J
Cancer Chemother Pharmacol; 2018 Sep; 82(3):421-428. PubMed ID: 29936608
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
[TBL] [Abstract][Full Text] [Related]
18. Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients.
Palugulla S; Thakkar DN; Kayal S; Narayan SK; Dkhar SA
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3157-3165. PubMed ID: 29172294
[TBL] [Abstract][Full Text] [Related]
19. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
